1
|
Caragut RL, Ilie M, Cabel T, Günșahin D, Panaitescu A, Pavel C, Plotogea OM, Rînja EM, Constantinescu G, Sandru V. Updates in Diagnosis and Endoscopic Management of Cholangiocarcinoma. Diagnostics (Basel) 2024; 14:490. [PMID: 38472961 DOI: 10.3390/diagnostics14050490] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2023] [Revised: 02/10/2024] [Accepted: 02/17/2024] [Indexed: 03/14/2024] Open
Abstract
Cholangiocarcinoma (CCA) is an adenocarcinoma originating from the epithelial cells of the bile ducts/hepatocytes or peribiliary glands. There are three types of cholangiocarcinoma: intrahepatic, perihilar and distal. CCA represents approximately 3% of the gastrointestinal malignancies. The incidence of CCA is higher in regions of the Eastern world compared to the Western countries. There are multiple risk factors associated with cholangiocarcinoma such as liver fluke, primary sclerosing cholangitis, chronic hepatitis B, liver cirrhosis and non-alcoholic fatty liver disease. Endoscopy plays an important role in the diagnosis and management of cholangiocarcinoma. The main endoscopic methods used for diagnosis, biliary drainage and delivering intrabiliary local therapies are endoscopic retrograde cholangiopancreatography and endoscopic ultrasound. The purpose of this review is to analyze the current data found in literature about cholangiocarcinoma, with a focus on the actual diagnostic tools and endoscopic management options.
Collapse
Affiliation(s)
- Roxana-Luiza Caragut
- Clinical Department of Gastroenterology, Bucharest Emergency Clinical Hospital, 014461 Bucharest, Romania
| | - Madalina Ilie
- Clinical Department of Gastroenterology, Bucharest Emergency Clinical Hospital, 014461 Bucharest, Romania
- Department of Gastroenterology, University of Medicine and Pharmacy "Carol Davila" Bucharest, 050474 Bucharest, Romania
| | - Teodor Cabel
- Clinical Department of Gastroenterology, Bucharest Emergency Clinical Hospital, 014461 Bucharest, Romania
| | - Deniz Günșahin
- Clinical Department of Gastroenterology, Bucharest Emergency Clinical Hospital, 014461 Bucharest, Romania
| | - Afrodita Panaitescu
- Clinical Department of Gastroenterology, Bucharest Emergency Clinical Hospital, 014461 Bucharest, Romania
| | - Christopher Pavel
- Clinical Department of Gastroenterology, Bucharest Emergency Clinical Hospital, 014461 Bucharest, Romania
- Department of Gastroenterology, University of Medicine and Pharmacy "Carol Davila" Bucharest, 050474 Bucharest, Romania
| | - Oana Mihaela Plotogea
- Clinical Department of Gastroenterology, Bucharest Emergency Clinical Hospital, 014461 Bucharest, Romania
- Department of Gastroenterology, University of Medicine and Pharmacy "Carol Davila" Bucharest, 050474 Bucharest, Romania
| | - Ecaterina Mihaela Rînja
- Clinical Department of Gastroenterology, Bucharest Emergency Clinical Hospital, 014461 Bucharest, Romania
| | - Gabriel Constantinescu
- Clinical Department of Gastroenterology, Bucharest Emergency Clinical Hospital, 014461 Bucharest, Romania
- Department of Gastroenterology, University of Medicine and Pharmacy "Carol Davila" Bucharest, 050474 Bucharest, Romania
| | - Vasile Sandru
- Clinical Department of Gastroenterology, Bucharest Emergency Clinical Hospital, 014461 Bucharest, Romania
- Department of Gastroenterology, University of Medicine and Pharmacy "Carol Davila" Bucharest, 050474 Bucharest, Romania
| |
Collapse
|
2
|
Pavel C, Diculescu MM, Stepan AE, Constantinescu G, Sandru V, Ţieranu CG, Tomescu L, Constantinescu A, Patoni C, Plotogea OM, Ilie M. Considering Histologic Remission in Ulcerative Colitis as a Long-Term Target. J Clin Med 2024; 13:289. [PMID: 38202296 PMCID: PMC10780018 DOI: 10.3390/jcm13010289] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2023] [Revised: 12/17/2023] [Accepted: 12/31/2023] [Indexed: 01/12/2024] Open
Abstract
Monitoring disease activity in inflammatory bowel disease (IBD) is challenging since clinical manifestations do not represent reliable surrogates for an accurate reflection of the inflammatory burden. Endoscopic remission had been the most significant endpoint target in the last years; nevertheless, a remarkable proportion of patients continue to relapse despite a normal-appearing mucosa, highlighting that endoscopy may underestimate the true extent of the disease. A subtle hint of the importance that histology plays in the long-term course of the disease has been endorsed by the STRIDE-II consensus, which recommends considering histologic healing for ulcerative colitis (UC), even though it is not stated to be a compulsory formal target. It is a continuum-changing paradigm, and it is almost a certainty that in the near future, histologic healing may become the new formal target for ulcerative colitis. It must be emphasized that there is great heterogeneity in defining histological remission, and the main criteria or cut-off values for inflammatory markers are still in an ill-defined area. The complexity of some histologic scores is a source of confusion among clinicians and pathologists, leading to low adherence in clinical practice when it comes to a homogenous histopathological report. Therefore, a standardized and more practical approach is urgently needed.
Collapse
Affiliation(s)
- Christopher Pavel
- Department of Gastroenterology, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania; (C.P.); (M.M.D.); (G.C.); (V.S.); (C.G.Ţ.); (A.C.); (C.P.); (M.I.)
- Department of Gastroenterology, Clinical Emergency Hospital of Bucharest, 014461 Bucharest, Romania
| | - Mircea Mihai Diculescu
- Department of Gastroenterology, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania; (C.P.); (M.M.D.); (G.C.); (V.S.); (C.G.Ţ.); (A.C.); (C.P.); (M.I.)
- Department of Gastroenterology, Fundeni Clinical Institute, 022328 Bucharest, Romania
| | - Alex-Emilian Stepan
- Department of Pathology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania;
| | - Gabriel Constantinescu
- Department of Gastroenterology, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania; (C.P.); (M.M.D.); (G.C.); (V.S.); (C.G.Ţ.); (A.C.); (C.P.); (M.I.)
- Department of Gastroenterology, Clinical Emergency Hospital of Bucharest, 014461 Bucharest, Romania
| | - Vasile Sandru
- Department of Gastroenterology, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania; (C.P.); (M.M.D.); (G.C.); (V.S.); (C.G.Ţ.); (A.C.); (C.P.); (M.I.)
- Department of Gastroenterology, Clinical Emergency Hospital of Bucharest, 014461 Bucharest, Romania
| | - Cristian George Ţieranu
- Department of Gastroenterology, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania; (C.P.); (M.M.D.); (G.C.); (V.S.); (C.G.Ţ.); (A.C.); (C.P.); (M.I.)
- Department of Gastroenterology, “Elias” Emergency University Hospital, 011461 Bucharest, Romania
| | - Luiza Tomescu
- Department of Pathology, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania;
- Oncology Institute “Prof. Dr. Alexandru Trestioreanu”, 022328 Bucharest, Romania
| | - Alexandru Constantinescu
- Department of Gastroenterology, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania; (C.P.); (M.M.D.); (G.C.); (V.S.); (C.G.Ţ.); (A.C.); (C.P.); (M.I.)
- Department of Gastroenterology, Emergency University Hospital, 050098 Bucharest, Romania
| | - Cristina Patoni
- Department of Gastroenterology, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania; (C.P.); (M.M.D.); (G.C.); (V.S.); (C.G.Ţ.); (A.C.); (C.P.); (M.I.)
- Department of Gastroenterology, Central Military Emergency Hospital “Dr. Carol Davila”, 010825 Bucharest, Romania
| | - Oana-Mihaela Plotogea
- Department of Gastroenterology, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania; (C.P.); (M.M.D.); (G.C.); (V.S.); (C.G.Ţ.); (A.C.); (C.P.); (M.I.)
- Department of Gastroenterology, Clinical Emergency Hospital of Bucharest, 014461 Bucharest, Romania
| | - Madalina Ilie
- Department of Gastroenterology, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania; (C.P.); (M.M.D.); (G.C.); (V.S.); (C.G.Ţ.); (A.C.); (C.P.); (M.I.)
- Department of Gastroenterology, Clinical Emergency Hospital of Bucharest, 014461 Bucharest, Romania
| |
Collapse
|
3
|
Plotogea OM, Ilie M, Bungau S, Chiotoroiu AL, Stanescu AMA, Diaconu CC. Comprehensive Overview of Sleep Disorders in Patients with Chronic Liver Disease. Brain Sci 2021; 11:brainsci11020142. [PMID: 33499194 PMCID: PMC7911845 DOI: 10.3390/brainsci11020142] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2020] [Revised: 01/16/2021] [Accepted: 01/19/2021] [Indexed: 12/12/2022] Open
Abstract
The impact of sleep disorders (SDs) on patients with chronic liver diseases (CLD) is tremendous. SDs are frequently encountered among these patients and interfere with their quality of life. This review aims to present the data available so far about the prevalence, phenotypes, and proposed pathophysiological mechanisms of SDs in CLD. Moreover, we proposed to search the literature regarding the most reliable methods to assess SDs and the possible therapeutic options in patients with CLD. The main results of this review show that when it comes to prevalence, the percentages reported vary widely between studies performed among populations from the USA or Europe and those coming from Asian countries. Furthermore, it has been proven that SDs may also be present in the absence of neurocognitive disorders attributable to hepatic encephalopathy (HE), which contradicts traditional suppositions where SDs were considered part of the clinical scenario of HE. Currently, there are no specific recommendations or protocols to assess SDs in CLD patients and data about the therapeutic management are limited. Taking into consideration their impact, a protocol for diagnosing and managing SDs should be developed and included in the daily practice of hepatologists.
Collapse
Affiliation(s)
- Oana-Mihaela Plotogea
- Department 5, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania;
- Department of Gastroenterology, Clinical Emergency Hospital of Bucharest, 105402 Bucharest, Romania
- Correspondence: (O.-M.P.); (C.C.D.)
| | - Madalina Ilie
- Department 5, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania;
- Department of Gastroenterology, Clinical Emergency Hospital of Bucharest, 105402 Bucharest, Romania
| | - Simona Bungau
- Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, 410028 Oradea, Romania;
| | | | | | - Camelia Cristina Diaconu
- Department 5, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania;
- Department of Internal Medicine, Clinical Emergency Hospital of Bucharest, 105402 Bucharest, Romania
- Correspondence: (O.-M.P.); (C.C.D.)
| |
Collapse
|
4
|
Gheorghe G, Ilie M, Bungau S, Stoian AMP, Bacalbasa N, Diaconu CC. Is There a Relationship between COVID-19 and Hyponatremia? Medicina (Kaunas) 2021; 57:55. [PMID: 33435405 PMCID: PMC7827825 DOI: 10.3390/medicina57010055] [Citation(s) in RCA: 29] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/13/2020] [Revised: 01/05/2021] [Accepted: 01/05/2021] [Indexed: 02/07/2023]
Abstract
Nowadays, humanity faces one of the most serious health crises, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. The severity of coronavirus disease 2019 (COVID-19) pandemic is related to the high rate of interhuman transmission of the virus, variability of clinical presentation, and the absence of specific therapeutic methods. COVID-19 can manifest with non-specific symptoms and signs, especially among the elderly. In some cases, the clinical manifestations of hyponatremia may be the first to appear. The pathophysiological mechanisms of hyponatremia among patients with COVID-19 are diverse, including syndrome of inappropriate antidiuretic hormone secretion (SIADH), digestive loss of sodium ions, reduced sodium ion intake or use of diuretic therapy. Hyponatremia may also be considered a negative prognostic factor in patients diagnosed with COVID-19. We need further studies to evaluate the etiology and therapeutic management of hyponatremia in patients with COVID-19.
Collapse
Affiliation(s)
- Gina Gheorghe
- Department of Gastroenterology, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania; (G.G.); (M.I.)
- Department of Gastroenterology, Clinical Emergency Hospital of Bucharest, 105402 Bucharest, Romania
| | - Madalina Ilie
- Department of Gastroenterology, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania; (G.G.); (M.I.)
- Department of Gastroenterology, Clinical Emergency Hospital of Bucharest, 105402 Bucharest, Romania
| | - Simona Bungau
- Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, 410028 Oradea, Romania;
| | - Anca Mihaela Pantea Stoian
- Department of Diabetes, Nutrition and Metabolic Diseases, “Carol Davila” University of Medicine and Pharmacy, 020475 Bucharest, Romania;
| | - Nicolae Bacalbasa
- Department of Visceral Surgery, Center of Excellence in Translational Medicine, Fundeni Clinical Institute, 022328 Bucharest, Romania;
| | - Camelia Cristina Diaconu
- Department of Internal Medicine, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania
- Department of Internal Medicine, Clinical Emergency Hospital of Bucharest, 105402 Bucharest, Romania
| |
Collapse
|
5
|
Seicean A, Pojoga C, Mostean O, Bolboaca S, Ilie M, Rimbas M, Gheorghiu M, Lucaciu L, Bartos A, Al Hajjar N, Sandru V, Constantinescu G, Seicean R. What is the Impact of the Proportion of Solid Necrotic Content on the Number of Necrosectomies during EUS-Guided Drainage using Lumen-Apposing Metallic Stents of Pancreatic Walled-off Necrosis ? J Gastrointestin Liver Dis 2020; 29:623-628. [PMID: 33331355 DOI: 10.15403/jgld-3128] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/15/2020] [Accepted: 10/19/2020] [Indexed: 11/01/2022]
Abstract
BACKGROUND AND AIMS The fully-covered, lumen apposing metal stents are designed for one step placement, facilitating the direct endoscopic necrosectomy into the walled-off pancreatic necrosis. However, the prediction of the number of necrosectomy sessions in these patients is not known. This study evaluated the association between the proportion of solid necrotic material inside walled-off necrosis, as assessed during the endosonography placement of a lumen apposing metal stent, and the number of necrosectomies subsequently required. METHODS Patients from three tertiary medical centers with symptomatic walled off pancreatic necrosis (pain, infection, gastric/biliary obstruction) at more than 4 weeks after onset of acute pancreatitis were retrospectively analysed. Proportion of solid necrotic debris was estimated during endosonography procedure of lumen apposing metal stents placement. Necrosectomy was performed when obstruction or inflammation occurred subsequently. Lumen apposing metal stents were removed after clearance of necrotic content. RESULTS In 46 patients with successful lumen apposing metal stents placement, necrosectomy was performed in 39 patients (72.78%). Performance of 3 or more necrosectomies was significantly associated with more than 50% pancreatic necrosis (p=0.032), but not with walled-off pancreatic necrosis size or location. Necrotic infection during lumen apposing metal stents stenting was associated with hypoalbuminemia, but not with necrosectomy requirement. Clinical success after a median follow-up of 13.37 months was 87%. CONCLUSIONS Walled-off pancreatic necrosis with more than 50% solid necrotic content were associated with more necrosectomy procedures, requiering longer endoscopy time, intravenous sedations, and higher costs.
Collapse
Affiliation(s)
- Andrada Seicean
- Iuliu Hațieganu University of Medicine and Pharmacy Cluj-Napoca; Regional Institute of Gastroenterology and Hepatology, Cluj-Napoca, Romania.
| | - Cristina Pojoga
- Regional Institute of Gastroenterology and Hepatology, Cluj-Napoca; Clinical Psychology and Psychotherapy Department Babes-Bolyai University Cluj- Napoca, Romania.
| | - Ofelia Mostean
- Iuliu Hațieganu University of Medicine and Pharmacy Cluj-Napoca; Regional Institute of Gastroenterology and Hepatology, Cluj-Napoca, Romania.
| | - Sorana Bolboaca
- Department of Medical Informatics and Biostatistics, Iuliu Hațieganu University of Medicine and Pharmacy Cluj-Napoca, Romania.
| | - Madalina Ilie
- Carol Davila University of Medicine and Pharmacy, Bucharest; Floreasca Emergency Hospital, Bucharest, Romania.
| | - Mihai Rimbas
- Carol Davila University of Medicine and Pharmacy, Bucharest; Colentina Clinical Hospital, Bucharest, Romania.
| | - Marcel Gheorghiu
- Iuliu Hațieganu University of Medicine and Pharmacy Cluj-Napoca, Romania.
| | - Laura Lucaciu
- Iuliu Hațieganu University of Medicine and Pharmacy Cluj-Napoca, Romania.
| | - Adrian Bartos
- Iuliu Hațieganu University of Medicine and Pharmacy Cluj-Napoca; Regional Institute of Gastroenterology and Hepatology, Cluj-Napoca, Romania.
| | - Nadim Al Hajjar
- Iuliu Hațieganu University of Medicine and Pharmacy Cluj-Napoca; Regional Institute of Gastroenterology and Hepatology, Cluj-Napoca, Romania.
| | - Vasile Sandru
- Carol Davila University of Medicine and Pharmacy, Bucharest; Floreasca Emergency Hospital, Bucharest, Romania.
| | - Gabriel Constantinescu
- Carol Davila University of Medicine and Pharmacy, Bucharest; Floreasca Emergency Hospital, Bucharest, Romania.
| | - Radu Seicean
- Iuliu Hațieganu University of Medicine and Pharmacy Cluj-Napoca; First Surgical Clinic, Cluj-Napoca, Romania.
| |
Collapse
|
6
|
Gheorghe G, Gheorghe F, Ceobanu G, Juganaru V, Ilie M, Bacalbasa N, Bratu OG, Diaconu CC. The infection with new coronavirus SARS-CoV-2. Ro J Med Pract 2020. [DOI: 10.37897/rjmp.2020.1.6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
7
|
Bence C, Hofman V, Chamorey E, Long-Mira E, Lassalle S, Albertini AF, Liolios I, Zahaf K, Picard A, Montaudié H, Lacour JP, Passeron T, Andea AA, Ilie M, Hofman P. Association of combined PD-L1 expression and tumour-infiltrating lymphocyte features with survival and treatment outcomes in patients with metastatic melanoma. J Eur Acad Dermatol Venereol 2019; 34:984-994. [PMID: 31625630 DOI: 10.1111/jdv.16016] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2019] [Accepted: 09/20/2019] [Indexed: 12/24/2022]
Abstract
BACKGROUND Recent advances obtained with immune checkpoint inhibitors (ICIs) targeting the programmed cell death-1 (PD-1) protein have significantly improved the outcome of patients with metastatic melanoma. The PD-L1 expression in tumour cells as detected by immunohistochemistry is a predictive biomarker in some solid tumours, but appears insufficient as prognostic or predictive factor of response to ICIs in metastatic melanomas. OBJECTIVES We investigated whether the presence and the features of pretreatment CD8+ tumour-infiltrating T lymphocytes (TILs) could be a complementary prognostic or predictive biomarker in patients with metastatic melanoma. METHODS In this retrospective study, we evaluated the association of PD-L1 expression ≥5% of tumour cells combined with TIL features (CD8, CD28, Ki67) with the overall survival (OS) among 51 patients treated with ICIs and 54 patients treated with other treatment options (non-ICIs). RESULTS PD-L1 positivity was observed in 33% and 39% of primary melanomas and matched metastases, respectively, with, however, poor concordance between the primary and the matched metastatic site (κ = 0.283). No significant association was noted between PD-L1 expression and CD8+ TIL profile analysed as single markers and OS or response to immunotherapy. Instead, their combined analysis in primary melanoma samples showed that the PD-L1-/CD8+ status was significantly associated with prolonged OS in the whole population (P = 0.04) and in the subgroup treated with non-ICIs (P = 0.009). Conversely, the PD-L1+/CD8+ status was a good prognostic factor in patients treated with ICIs (P = 0.022), whereas was significantly associated with poor prognosis in patients treated with non-ICIs (P = 0.014). While the expression of CD28 was not related to outcome, the Ki67 expression was significantly associated with poor OS in the subgroup CD8+ TIL+/PD-L1- (P = 0.02). CONCLUSIONS The pretreatment combination of PD-L1 expression with the level of CD8+ TILs could better assess OS and predict therapeutic response of patients with metastatic melanoma treated by either immunotherapy or other treatment regimens.
Collapse
Affiliation(s)
- C Bence
- Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, Université Côte d'Azur, University Hospital Federation OncoAge, Nice, France
| | - V Hofman
- Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, Université Côte d'Azur, University Hospital Federation OncoAge, Nice, France.,CNRS, INSERM, Institute of Research on Cancer and Ageing of Nice (IRCAN), Université Côte d'Azur, University Hospital Federation OncoAge, Nice, France.,Hospital-Related Biobank (BB-0033-00025), Pasteur Hospital, Université Côte d'Azur, University Hospital Federation OncoAge, Nice, France
| | - E Chamorey
- Biostatistics Unit, Antoine Lacassagne Comprehensive Cancer Center, Nice, France
| | - E Long-Mira
- Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, Université Côte d'Azur, University Hospital Federation OncoAge, Nice, France.,CNRS, INSERM, Institute of Research on Cancer and Ageing of Nice (IRCAN), Université Côte d'Azur, University Hospital Federation OncoAge, Nice, France.,Hospital-Related Biobank (BB-0033-00025), Pasteur Hospital, Université Côte d'Azur, University Hospital Federation OncoAge, Nice, France
| | - S Lassalle
- Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, Université Côte d'Azur, University Hospital Federation OncoAge, Nice, France.,CNRS, INSERM, Institute of Research on Cancer and Ageing of Nice (IRCAN), Université Côte d'Azur, University Hospital Federation OncoAge, Nice, France.,Hospital-Related Biobank (BB-0033-00025), Pasteur Hospital, Université Côte d'Azur, University Hospital Federation OncoAge, Nice, France
| | | | | | - K Zahaf
- Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, Université Côte d'Azur, University Hospital Federation OncoAge, Nice, France
| | - A Picard
- Department of Dermatology, Archet Hospital, Université Côte d'Azur, Nice, France
| | - H Montaudié
- Department of Dermatology, Archet Hospital, Université Côte d'Azur, Nice, France
| | - J P Lacour
- Department of Dermatology, Archet Hospital, Université Côte d'Azur, Nice, France
| | - T Passeron
- Department of Dermatology, Archet Hospital, Université Côte d'Azur, Nice, France
| | - A A Andea
- Department of Pathology, Michigan Medicine, University of Michigan, Ann Arbor, MI, USA
| | - M Ilie
- Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, Université Côte d'Azur, University Hospital Federation OncoAge, Nice, France.,CNRS, INSERM, Institute of Research on Cancer and Ageing of Nice (IRCAN), Université Côte d'Azur, University Hospital Federation OncoAge, Nice, France.,Hospital-Related Biobank (BB-0033-00025), Pasteur Hospital, Université Côte d'Azur, University Hospital Federation OncoAge, Nice, France
| | - P Hofman
- Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, Université Côte d'Azur, University Hospital Federation OncoAge, Nice, France.,CNRS, INSERM, Institute of Research on Cancer and Ageing of Nice (IRCAN), Université Côte d'Azur, University Hospital Federation OncoAge, Nice, France.,Hospital-Related Biobank (BB-0033-00025), Pasteur Hospital, Université Côte d'Azur, University Hospital Federation OncoAge, Nice, France
| |
Collapse
|
8
|
Humbert O, Cadour N, Paquet M, Schiappa R, Poudenx M, Chardin D, Borchiellini D, Benisvy D, Ouvrier MJ, Zwarthoed C, Schiazza A, Ilie M, Ghalloussi H, Koulibaly PM, Darcourt J, Otto J. 18FDG PET/CT in the early assessment of non-small cell lung cancer response to immunotherapy: frequency and clinical significance of atypical evolutive patterns. Eur J Nucl Med Mol Imaging 2019; 47:1158-1167. [PMID: 31760467 DOI: 10.1007/s00259-019-04573-4] [Citation(s) in RCA: 54] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2019] [Accepted: 10/10/2019] [Indexed: 12/11/2022]
Abstract
PURPOSE This prospective study aimed (1) to assess the non-small cell lung cancer (NSCLC) evolutive patterns to immunotherapy using FDG-PET and (2) to describe their association with clinical outcome. DESIGN Fifty patients with metastatic NSCLC were included before pembrolizumab or nivolumab initiation. FDG-PET scan was performed at baseline and after 7 weeks of treatment (PETinterim1) and different criteria/parameters of tumor response were assessed, including PET response criteria in solid tumors (PERCIST). If a first PERCIST progressive disease (PD) without clinical worsening was observed, treatment was continued and a subsequent FDG-PET (PETinterim2) was performed at 3 months of treatment. Pseudo-progression (PsPD) was defined as a PERCIST response/stability on PETinterim2 after an initial PD. If a second PERCIST PD was assessed on PETinterim2, a homogeneous progression of lesions (termed immune homogeneous progressive-disease: iPDhomogeneous) was distinguished from a heterogeneous evolution (termed immune dissociated-response: iDR). A durable clinical benefit (DCB) of immunotherapy was defined as treatment continuation over a 6-month period. The association between PET evolutive profiles and DCB was assessed. RESULTS Using PERCIST on PETinterim1, 42% (21/50) of patients showed a response or stable disease, most of them (18/21) reached a DCB. In contrast, 58% (29/50) showed a PD, but more than one-third (11/29) were misclassified as they finally reached a DCB. No standard PETinterim1 criteria could accurately distinguished responding from non-responding patients. Treatment was continued in 19/29 of patients with a first PERCIST PD; the subsequent PETinterim2 demonstrated iPDhomogeneous, iDR and PsPD in 42% (8/19), 26% (5/19), and 32% (6/19), respectively. Whereas no patients with iPDhomogeneous experienced a DCB, all patients with iDR and PsPD reached a clinical benefit to immunotherapy. CONCLUSION In patients with a first PD on PERCIST and treatment continuation, a subsequent PET identifies more than half of them with iDR and PsPD, both patterns being strongly associated with a clinical benefit of immunotherapy.
Collapse
Affiliation(s)
- O Humbert
- Department of Nuclear Medicine, Centre Antoine-Lacassagne, Université Côte d'Azur (UCA), 33 Avenue de Valombrose, 06189, Nice, France. .,Laboratory Transporter in Imaging and Radiotherapy in Oncology (TIRO), UMR E 4320, CEA, UCA, Nice, France.
| | - N Cadour
- Department of Nuclear Medicine, Centre Antoine-Lacassagne, Université Côte d'Azur (UCA), 33 Avenue de Valombrose, 06189, Nice, France
| | - M Paquet
- Department of Nuclear Medicine, Centre Antoine-Lacassagne, Université Côte d'Azur (UCA), 33 Avenue de Valombrose, 06189, Nice, France
| | - R Schiappa
- Department of Biostatistics, Centre Antoine-Lacassagne, UCA, Nice, France
| | - M Poudenx
- Department of Medical Oncology, Centre Antoine-Lacassagne, UCA, Nice, France
| | - D Chardin
- Department of Nuclear Medicine, Centre Antoine-Lacassagne, Université Côte d'Azur (UCA), 33 Avenue de Valombrose, 06189, Nice, France.,Laboratory Transporter in Imaging and Radiotherapy in Oncology (TIRO), UMR E 4320, CEA, UCA, Nice, France
| | - D Borchiellini
- Department of Medical Oncology, Centre Antoine-Lacassagne, UCA, Nice, France.,Clinical Research and Innovation Office, Centre Antoine-Lacassagne, UCA, Nice, France
| | - D Benisvy
- Department of Nuclear Medicine, Centre Antoine-Lacassagne, Université Côte d'Azur (UCA), 33 Avenue de Valombrose, 06189, Nice, France
| | - M J Ouvrier
- Department of Nuclear Medicine, Centre Antoine-Lacassagne, Université Côte d'Azur (UCA), 33 Avenue de Valombrose, 06189, Nice, France
| | - C Zwarthoed
- Department of Nuclear Medicine, Centre Antoine-Lacassagne, Université Côte d'Azur (UCA), 33 Avenue de Valombrose, 06189, Nice, France
| | - A Schiazza
- Department of Nuclear Medicine, Centre Antoine-Lacassagne, Université Côte d'Azur (UCA), 33 Avenue de Valombrose, 06189, Nice, France
| | - M Ilie
- Laboratory of Clinical and Experimental Pathology, Hospital-Integrated Biobank (BB-0033-00025), Nice Hospital University, FHU OncoAge, UCA, Nice, France
| | - H Ghalloussi
- Department of Medical Oncology, Centre Antoine-Lacassagne, UCA, Nice, France
| | - P M Koulibaly
- Department of Nuclear Medicine, Centre Antoine-Lacassagne, Université Côte d'Azur (UCA), 33 Avenue de Valombrose, 06189, Nice, France
| | - J Darcourt
- Department of Nuclear Medicine, Centre Antoine-Lacassagne, Université Côte d'Azur (UCA), 33 Avenue de Valombrose, 06189, Nice, France.,Laboratory Transporter in Imaging and Radiotherapy in Oncology (TIRO), UMR E 4320, CEA, UCA, Nice, France
| | - J Otto
- Department of Medical Oncology, Centre Antoine-Lacassagne, UCA, Nice, France
| |
Collapse
|
9
|
Murgier M, Forest F, Savale L, Ilie M, Bertoletti L. Pulmonary hypertension due to pulmonary artery obstructions by malignant tumoral cells. Respir Med Res 2019; 76:10-12. [PMID: 31254944 DOI: 10.1016/j.resmer.2019.04.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2019] [Revised: 04/17/2019] [Accepted: 04/17/2019] [Indexed: 11/17/2022]
Affiliation(s)
- M Murgier
- Medical intensive care unit, Saint-ðtienne university hospital, 42270 Saint-Priest-en-Jarez, France.
| | - F Forest
- Pathology department, university hospital, 42270 Saint-Priest-en-Jarez, France; Corneal graft biology, engineering and imaging laboratory, BiiGC, EA2521, federative institute of research in sciences and health engineering, faculty of medicine, Jean-Monnet university, 42270 Saint-ðtienne, France
| | - L Savale
- Service de pneumologie, centre de référence de l⬢hypertension pulmonaire sévère, hôpital Bicêtre, AP⬜HP, 94270 Le Kremlin-Bicêtre, France; Inserm UMR_S 999, hôpital Marie-Lannelongue, 92350 Le Plessis-Robinson, France; Faculté de médecine, université Paris-Sud, université Paris-Saclay, 94270 Le Kremlin-Bicêtre, France
| | - M Ilie
- Laboratory of clinical and experimental pathology and Hospital-Integrated Biobank (BB-0033-00025), Pasteur Hospital, University Hospital Federation OncoAge, université Côte d⬢Azur, 06108 Nice, France
| | - L Bertoletti
- Department of vascular and therapeutic medicine, Saint-ðtienne university hospital, 42270 Saint-Priest-en-Jarez, France; Inserm CIC1408, 42270 Saint-ðtienne, France; INNOVTE, 42055 Saint-ðtienne, France
| |
Collapse
|
10
|
Ilie M, Benzaquen J, Hofman V, Lassalle S, Yazbeck N, Leroy S, Heeke S, Bence C, Mograbi B, Glaichenhaus N, Marquette CH, Hofman P. Immunotherapy in Non-Small Cell Lung Cancer: Biological Principles and Future Opportunities. Curr Mol Med 2019; 17:527-540. [PMID: 29473504 DOI: 10.2174/1566524018666180222114038] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2017] [Revised: 02/04/2018] [Accepted: 02/15/2018] [Indexed: 11/22/2022]
Abstract
Immunotherapy aims to amplify the anticancer immune response through reactivation of the lymphocytic response raised against several tumor neo-antigens. To obtain an effective immune response, this therapeutic approach requires that a number of immunological checkpoints be passed, such as the activation of excitatory costimulatory signals or the avoidance of coinhibitory molecules. Among the immune checkpoints, the interaction of the membrane-bound ligand PD-1 and its receptor PD-L1 has received much attention because of remarkable efficacy in numerous clinical trials for various cancer types, including non-small cell lung cancer (NSCLC). However, several limitations exist with these therapeutic agents when used as monotherapy, with objective responses observed in only 30-40% of patients, with the majority of patients demonstrating innate resistance, and approximately 25% of responders later demonstrating disease progression. Recent developments in the understanding of cancer immunology have the potential to identify mechanisms of innate and acquired resistance to immune checkpoint inhibitors through translational research in human samples. This review focuses on the biological basic principles for immunological checkpoint blockade, and highlights the current status and the perspectives of this therapeutic approach in NSCLC patients.
Collapse
Affiliation(s)
- M Ilie
- University Cote d'Azur, Nice Hospital, FHU OncoAge, Laboratory of Clinical and Experimental Pathology and Hospital-related Biobank (BB-0033-00025), 06001 Nice, France.,University Cote d'Azur, Inserm U1081/CNRS UMR 7284, Institute for Research on Cancer and Aging, Comprehensive Cancer Center Antoine Lacassagne, Nice, France
| | - J Benzaquen
- University Cote d'Azur, Inserm U1081/CNRS UMR 7284, Institute for Research on Cancer and Aging, Comprehensive Cancer Center Antoine Lacassagne, Nice, France.,University Cote d'Azur, Nice Hospital, FHU OncoAge, Pneumology Department, 06000 Nice, France
| | - V Hofman
- University Cote d'Azur, Nice Hospital, FHU OncoAge, Laboratory of Clinical and Experimental Pathology and Hospital-related Biobank (BB-0033-00025), 06001 Nice, France.,University Cote d'Azur, Inserm U1081/CNRS UMR 7284, Institute for Research on Cancer and Aging, Comprehensive Cancer Center Antoine Lacassagne, Nice, France
| | - S Lassalle
- University Cote d'Azur, Nice Hospital, FHU OncoAge, Laboratory of Clinical and Experimental Pathology and Hospital-related Biobank (BB-0033-00025), 06001 Nice, France.,University Cote d'Azur, Inserm U1081/CNRS UMR 7284, Institute for Research on Cancer and Aging, Comprehensive Cancer Center Antoine Lacassagne, Nice, France
| | - N Yazbeck
- University Cote d'Azur, Inserm U1081/CNRS UMR 7284, Institute for Research on Cancer and Aging, Comprehensive Cancer Center Antoine Lacassagne, Nice, France
| | - S Leroy
- University Cote d'Azur, Nice Hospital, FHU OncoAge, Pneumology Department, 06000 Nice, France
| | - S Heeke
- University Cote d'Azur, Inserm U1081/CNRS UMR 7284, Institute for Research on Cancer and Aging, Comprehensive Cancer Center Antoine Lacassagne, Nice, France
| | - C Bence
- University Cote d'Azur, Nice Hospital, FHU OncoAge, Laboratory of Clinical and Experimental Pathology and Hospital-related Biobank (BB-0033-00025), 06001 Nice, France
| | - B Mograbi
- University Cote d'Azur, Inserm U1081/CNRS UMR 7284, Institute for Research on Cancer and Aging, Comprehensive Cancer Center Antoine Lacassagne, Nice, France
| | - N Glaichenhaus
- University Cote d'Azur, FHU OncoAge, Cellular and Molecular Pharmacology Institute CNRS, INSERM, Valbonne, France
| | - C-H Marquette
- University Cote d'Azur, Inserm U1081/CNRS UMR 7284, Institute for Research on Cancer and Aging, Comprehensive Cancer Center Antoine Lacassagne, Nice, France.,University Cote d'Azur, Nice Hospital, FHU OncoAge, Pneumology Department, 06000 Nice, France
| | - P Hofman
- University Cote d'Azur, Nice Hospital, FHU OncoAge, Laboratory of Clinical and Experimental Pathology and Hospital-related Biobank (BB-0033-00025), 06001 Nice, France.,University Cote d'Azur, Inserm U1081/CNRS UMR 7284, Institute for Research on Cancer and Aging, Comprehensive Cancer Center Antoine Lacassagne, Nice, France
| |
Collapse
|
11
|
Rinja E, Ilie M, Sandru V, Diaconu I, Plotogea O, Hortopan A, Oprita R, Chiotoroiu AL, Constantinescu G. A rare case of multiple colonic ulcers revealed by hematochezia. Ro J Med Pract 2018. [DOI: 10.37897/rjmp.2018.3.8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
12
|
Oprisanescu D, Bucur D, Sandru V, Nedelcu IC, Ilie M, Oprita R, Constantinescu G. Endoscopic Treatment of Benign Esophageal Fistulas Using Fully-covered Metallic Esophageal Stents. Chirurgia (Bucur) 2018; 113:108-115. [DOI: 10.21614/chirurgia.113.1.108] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/01/2018] [Indexed: 11/23/2022]
|
13
|
Ilie M, Khambata-Ford S, Copie-Bergman C, Huang L, Mogg R, Juco J, Hofman V, Hofman P. Optimized protocols to determine PD-L1 expression on tumor tissue and cytology samples from non–small cell lung cancer (NSCLC) patients using the 22C3 antibody with various immunohistochemistry (IHC) autostainers. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx376.043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
14
|
Moleiro J, Ilie M, Fitzgerald R. Leadership roles for women in gastroenterology: New initiatives for the new generation of gastroenterologists. United European Gastroenterol J 2017; 4:815. [PMID: 28409000 DOI: 10.1177/2050640616669653] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Affiliation(s)
- Joana Moleiro
- Gastroenterology, Emergency Hospital, Bucharest, Romania
| | - Madalina Ilie
- Gastroenterology, Emergency Hospital, Bucharest, Romania.,UEG's Young Talent Group (YTG)
| | - Rebecca Fitzgerald
- Medical Research Council Cancer Unit, University of Cambridge, Cambridge, UK
| |
Collapse
|
15
|
Baibarac M, Ilie M, Baltog I, Lefrant S, Humbert B. Infrared dichroism studies and anisotropic photoluminescence properties of poly(para-phenylene vinylene) functionalized reduced graphene oxide. RSC Adv 2017. [DOI: 10.1039/c6ra26445j] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Polarized PL spectra of the composite based on 0.5 wt% RGO and PPV in un-doped state.
Collapse
Affiliation(s)
- M. Baibarac
- National Institute of Materials Physics
- Laboratory of Optical Processes in Nanostructured Materials
- Bucharest
- Romania
| | - M. Ilie
- National Institute of Materials Physics
- Laboratory of Optical Processes in Nanostructured Materials
- Bucharest
- Romania
- University of Bucharest
| | - I. Baltog
- National Institute of Materials Physics
- Laboratory of Optical Processes in Nanostructured Materials
- Bucharest
- Romania
| | - S. Lefrant
- Institut des Materiaux “Jean Rouxel”
- Nantes
- France
| | - B. Humbert
- Institut des Materiaux “Jean Rouxel”
- Nantes
- France
| |
Collapse
|
16
|
Seremet O, Nitulescu G, Ilie M, Olaru O. Toxicity research of certain plant extracts containing pyrrolizidine alkaloids using alternative invertebrates models. Toxicol Lett 2016. [DOI: 10.1016/j.toxlet.2016.06.1349] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
17
|
Olaru O, Nitulescu G, Spinu C, Potolea I, Pirvu O, Ilie M, Nitulescu G. The assessment of Ficaria verna acute toxicity by two alternative methods: Daphnia magna and Physella acuta bioassays. Toxicol Lett 2016. [DOI: 10.1016/j.toxlet.2016.06.1323] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
18
|
Văleanu A, Margină D, Grădinaru D, Ilie M. A fuzzy c-means and k-means clustering analysis on relevant diabetic retinopathy biomarkers. Toxicol Lett 2016. [DOI: 10.1016/j.toxlet.2016.06.1476] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
19
|
Gutu C, Olaru O, Purdel C, Margina D, Ilie M, Nitulescu G, Balalau D. Phytotoxicity of inorganic arsenic species assessed in vitro on Triticum and Lactuca species. Toxicol Lett 2016. [DOI: 10.1016/j.toxlet.2016.06.1314] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
20
|
Constantinescu G, Sandru V, Ilie M, Nedelcu C, Tincu R, Popa B. Treatment of Malignant Esophageal Fistulas: Fluoroscopic Placement of Esophageal SEMS, Endoscopically-assisted through Surgical Gastrostomy. A Case Report. J Gastrointestin Liver Dis 2016; 25:249-52. [PMID: 27308659 DOI: 10.15403/jgld.2014.1121.252.mlg] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]
Abstract
Progressive esophageal carcinoma can infiltrate the surrounding tissues with subsequent development of a fistula, most commonly between the esophagus and the respiratory tract. The endoscopic placement of covered self-expanding metallic stents (SEMS) is the treatment of choice for malignant esophageal fistulas and should be performed immediately, as a fistula formation represents a potential life-threatening complication. We report the case of a 64-year-old male diagnosed with esophageal carcinoma, who had a 20Fr surgical gastrostomy tube inserted before chemo- and radiotherapy and was referred to our department for complete dysphagia, cough after swallowing and fever. The attempt to insert a SEMS using the classic endoscopic procedure failed. Then, a fully covered stent was inserted, as the 0.035" guide wire was passed through stenosis retrogradely by using an Olympus Exera II GIF-N180 (4.9 mm in diameter endoscope) via surgical gastrostomy, with a good outcome for the patient. The retrograde approach via gastrostomy under endoscopic/fluoroscopic guidance with the placement of a fully covered SEMS proved to be the technique of choice, in a patient with malignant esophageal fistula in whom other methods of treatment were not feasible.
Collapse
Affiliation(s)
| | - Vasile Sandru
- Gastroenterology Department, Clinical Emergency Hospital Bucharest, Romania
| | - Madalina Ilie
- Gastroenterology Department, Clinical Emergency Hospital Bucharest, Romania
| | - Cristian Nedelcu
- Gastroenterology Department, Clinical Emergency Hospital Bucharest, Romania
| | - Radu Tincu
- Intensive Care Unit, Clinical Emergency Hospital Bucharest, Romania
| | - Bogdan Popa
- Radiology Department, Clinical Emergency Hospital Bucharest, Romania
| |
Collapse
|
21
|
Guibert N, Ilie M, Long E, Hofman V, Bouhlel L, Brest P, Mograbi B, Marquette CH, Didier A, Mazieres J, Hofman P. KRAS Mutations in Lung Adenocarcinoma: Molecular and Epidemiological Characteristics, Methods for Detection, and Therapeutic Strategy Perspectives. Curr Mol Med 2016; 15:418-32. [PMID: 25941815 DOI: 10.2174/1566524015666150505161412] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2014] [Revised: 04/10/2015] [Accepted: 04/28/2015] [Indexed: 11/22/2022]
Abstract
KRAS mutations are detected in over one third of lung adenocarcinomas, most frequently in Caucasian and smoker patients. The impact of KRAS mutations on lung adenocarcinoma prognosis is currently subject to debate, as is their impact on the response to chemotherapy and EGFR tyrosine kinase inhibitors. The different methods for KRAS status assessment, based on histological and cytological samples or biological fluids, offer varying sensitivities. Since no treatments are available in clinical routine for KRAS-mutated lung cancer patients, one of the current major challenges in thoracic oncology is developing new dedicated strategic therapies. Different molecules can be developed that act on a post-transcriptional KRAS protein level, blocking its cytoplasmic membrane recruitment. The efficacy of these molecules' targeting of the different signaling pathways activated by the KRAS mutation (such as the MEK and BRAF pathways) is related to the particular KRAS mutation subtype. New therapeutic strategies are currently focused on certain genes linked with KRAS inducing a synthetic lethal interaction. The purpose of this work is to provide an overview of i) the recent epidemiological and molecular findings concerning KRASmutated lung adenocarcinoma, ii) the prognostic impact of KRAS mutations, in particular during response to treatment, iii) the available methods for detecting this mutation, and iv) the current molecules under development for new therapeutic strategies and the clinical trials targeting this genomic alteration.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | - P Hofman
- Laboratoire de Pathologie Clinique et Experimentale, Hopital Pasteur, CHU de Nice, 30 avenue de la Voie Romaine, F-06002 Nice Cedex 1, France.
| |
Collapse
|
22
|
Popa B, Ilie M, Sandru V, Hortopan M, Beuran M, Constantinescu G. Endoscopic resection of a giant colonic lipoma causing severe anemia. J Gastrointestin Liver Dis 2016; 24:142. [PMID: 26114167 DOI: 10.15403/jgld.2014.1121.242.endr] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]
Affiliation(s)
| | - Madalina Ilie
- Gastroenterology Department, Clinical Emergency Hospital,Bucharest, Romania.
| | - Vasile Sandru
- Gastroenterology Department, Clinical Emergency Hospital,Bucharest, Romania
| | - Monica Hortopan
- Surgery Department, Clinical Emergency Hospital, Bucharest, Romania
| | - Mircea Beuran
- Surgery Department, Clinical Emergency Hospital, Bucharest, Romania
| | | |
Collapse
|
23
|
Firulescu S, Dima IE, Danciulescu-Miulescu R, Purdel CN, Ilie M, Margina D. CP-050 A compliance with diabetes mellitus treatment study in the case of polymedication. Eur J Hosp Pharm 2016. [DOI: 10.1136/ejhpharm-2016-000875.50] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
24
|
Ilie M, Long-Mira E, Bence C, Butori C, Lassalle S, Bouhlel L, Fazzalari L, Zahaf K, Lalvée S, Washetine K, Mouroux J, Vénissac N, Poudenx M, Otto J, Sabourin J, Marquette C, Hofman V, Hofman P. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Ann Oncol 2016; 27:147-53. [DOI: 10.1093/annonc/mdv489] [Citation(s) in RCA: 383] [Impact Index Per Article: 47.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2015] [Accepted: 10/06/2015] [Indexed: 12/23/2022] Open
|
25
|
Gradinaru D, Margina D, Ilie M, Borsa C, Ionescu C, Prada GI. Correlation between erythropoietin serum levels and erythrocyte susceptibility to lipid peroxidation in elderly with type 2 diabetes. Acta Physiol Hung 2015; 102:400-408. [PMID: 26690032 DOI: 10.1556/036.102.2015.4.7] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
Erythropoietin (EPO), a key hormone involved in red blood cell formation has been recently acknowledged for its pleiotropic actions and protective role in ageing and various pathological conditions concurrent with oxidative stress, vascular diseases and metabolic abnormalities such as diabetes mellitus. The aim of the study was to evaluate the relationship between circulating erythropoietin levels and oxidative stress biomarkers, in elderly with type 2 diabetes (T2DM). The study was carried out in 67 subjects with T2DM (69 ± 5 years; n = 37) without anemia, and aged-matched controls (70 ± 6 years; n = 30). EPO serum levels, erythrocyte susceptibility to lipid peroxidation (ESP) and total antioxidant capacity (TAC) were evaluated. Lower EPO levels (p < 0.01) and higher ESP values (p < 0.001) were found in T2DM group, compared to healthy subjects. EPO levels showed significant negative associations with ESP, both in T2DM subjects (r = -0.565; p < 0.001) and in all study population (r = -0,600; p < 0,001; n = 67). In conclusion, we provide new data regarding the cytoprotective effect of EPO exerted at systemic level on erythrocyte membrane, in the particular state of impaired glucose metabolism associated with oxidative stress, in the elderly.
Collapse
Affiliation(s)
- D Gradinaru
- Department of Biochemistry, Faculty of Pharmacy, Carol Davila-University of Medicine and Pharmacy , 6 Taian Vuia street, sector 2, 020956, Bucharest , Romania
- Ana Aslan-National Institute of Gerontology and Geriatrics , Bucharest , Romania
| | - D Margina
- Department of Biochemistry, Faculty of Pharmacy, Carol Davila-University of Medicine and Pharmacy , 6 Taian Vuia street, sector 2, 020956, Bucharest , Romania
| | - M Ilie
- Department of Biochemistry, Faculty of Pharmacy, Carol Davila-University of Medicine and Pharmacy , 6 Taian Vuia street, sector 2, 020956, Bucharest , Romania
| | - C Borsa
- Ana Aslan-National Institute of Gerontology and Geriatrics , Bucharest , Romania
| | - C Ionescu
- Ana Aslan-National Institute of Gerontology and Geriatrics , Bucharest , Romania
| | - G I Prada
- Department of Biochemistry, Faculty of Pharmacy, Carol Davila-University of Medicine and Pharmacy , 6 Taian Vuia street, sector 2, 020956, Bucharest , Romania
- Ana Aslan-National Institute of Gerontology and Geriatrics , Bucharest , Romania
| |
Collapse
|
26
|
Guibert N, Ilie M, Léna H, Didier A, Hofman P, Mazieres J. [KRAS and bronchial adenocarcinoma. Between disappointments and hopes]. Rev Mal Respir 2015; 33:156-64. [PMID: 26520779 DOI: 10.1016/j.rmr.2015.05.012] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2015] [Accepted: 05/05/2015] [Indexed: 12/20/2022]
Abstract
A better understanding of oncogenesis and the development of targeted therapies have led to improved outcomes in the treatment of lung cancer. KRAS mutation has the potential to drive the oncogenesis of almost one third of lung adenocarcinomas but it leads to a highly complex proliferation signal involving multiple signaling pathways, explaining the disappointing results of various inhibition strategies of K-ras or its effectors. Nevertheless, recent data suggest different roles of distinct KRAS mutation subtypes and KRAS interactions with new genes in the field of synthetic lethality mechanisms open the way to new therapeutic possibilities. This review aims to provide an overview of: 1) epidemiological data and particularly the prognostic impact of KRAS mutations in non-small cell lung cancer, 2) the results of different drugs either being tested in humans or sources of hope.
Collapse
Affiliation(s)
- N Guibert
- Unité d'oncologie cervico-thoracique-clinique des voies respiratoires, service de pneumologie, hôpital Larrey, université Paul-Sabatier, CHU de Toulouse, chemin de Pouvourville, 31059 Toulouse cedex, France.
| | - M Ilie
- Laboratoire de pathologie clinique et expérimentale, hôpital Pasteur, 06000 Nice, France
| | - H Léna
- Service de pneumologie, hôpital Pontchaillou, CHU de Rennes, 35000 Rennes, France
| | - A Didier
- Unité d'oncologie cervico-thoracique-clinique des voies respiratoires, service de pneumologie, hôpital Larrey, université Paul-Sabatier, CHU de Toulouse, chemin de Pouvourville, 31059 Toulouse cedex, France
| | - P Hofman
- Laboratoire de pathologie clinique et expérimentale, hôpital Pasteur, 06000 Nice, France
| | - J Mazieres
- Unité d'oncologie cervico-thoracique-clinique des voies respiratoires, service de pneumologie, hôpital Larrey, université Paul-Sabatier, CHU de Toulouse, chemin de Pouvourville, 31059 Toulouse cedex, France
| |
Collapse
|
27
|
Margina D, Olaru O, Gutu C, Florea L, Gradinaru D, Purdel C, Ilie M. Effects induced by natural extracts on Daphnia magna exposed to UV toxicity. Toxicol Lett 2015. [DOI: 10.1016/j.toxlet.2015.08.823] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
28
|
Margina D, Olaru O, Ilie M, Gutu C, Petrache S, Florea L, Gradinaru D, Dinischiotu A. Effects induced by polyphenol-rich natural extracts against lipoperoxidation – Protection against toxicant induced oxidative stress. Toxicol Lett 2015. [DOI: 10.1016/j.toxlet.2015.08.241] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
29
|
Valeanu A, Purdel C, Dima I, Margina D, Ilie M. The pattern of carbonylated human serum albumin using cluster analysis. Toxicol Lett 2015. [DOI: 10.1016/j.toxlet.2015.08.575] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
30
|
Long E, Ilie M, Lassalle S, Butori C, Poissonnet G, Washetine K, Mouroux J, Lespinet V, Lacour J, Taly V, Laurent-Puig P, Bahadoran P, Hofman V, Hofman P. Why and how immunohistochemistry should now be used to screen for the BRAFV600E status in metastatic melanoma? The experience of a single institution (LCEP, Nice, France). J Eur Acad Dermatol Venereol 2015; 29:2436-43. [DOI: 10.1111/jdv.13332] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2015] [Accepted: 07/07/2015] [Indexed: 12/15/2022]
Affiliation(s)
- E. Long
- Laboratory of Clinical and Experimental Pathology; Pasteur Hospital; Nice Cedex France
- Institute for Research on Cancer and Aging; Nice (IRCAN) CNRS UMR 7284/Inserm U1081; University of Nice Sophia Antipolis; Nice France
| | - M. Ilie
- Laboratory of Clinical and Experimental Pathology; Pasteur Hospital; Nice Cedex France
- Institute for Research on Cancer and Aging; Nice (IRCAN) CNRS UMR 7284/Inserm U1081; University of Nice Sophia Antipolis; Nice France
| | - S. Lassalle
- Laboratory of Clinical and Experimental Pathology; Pasteur Hospital; Nice Cedex France
- Institute for Research on Cancer and Aging; Nice (IRCAN) CNRS UMR 7284/Inserm U1081; University of Nice Sophia Antipolis; Nice France
| | - C. Butori
- Laboratory of Clinical and Experimental Pathology; Pasteur Hospital; Nice Cedex France
| | - G. Poissonnet
- Department of Surgery; CLCC Antoine Lacassagne Center; Nice France
| | - K. Washetine
- Laboratory of Clinical and Experimental Pathology; Pasteur Hospital; Nice Cedex France
- Nice Hospital-Related Biobank BB-0033-00025; Pasteur Hospital; Nice France
| | - J. Mouroux
- Institute for Research on Cancer and Aging; Nice (IRCAN) CNRS UMR 7284/Inserm U1081; University of Nice Sophia Antipolis; Nice France
- Department of Thoracic Surgery; Pasteur Hospital; Nice France
| | - V. Lespinet
- Laboratory of Clinical and Experimental Pathology; Pasteur Hospital; Nice Cedex France
| | - J.P. Lacour
- Department of Dermatology; Archet Hospital; Nice France
| | - V. Taly
- INSERM UMR-S1147; Centre Universitaire des Saints-Pères; University Paris Sorbonne Cité; Paris France
| | - P. Laurent-Puig
- INSERM UMR-S1147; Centre Universitaire des Saints-Pères; University Paris Sorbonne Cité; Paris France
| | - P. Bahadoran
- Department of Dermatology; Archet Hospital; Nice France
| | - V. Hofman
- Laboratory of Clinical and Experimental Pathology; Pasteur Hospital; Nice Cedex France
- Institute for Research on Cancer and Aging; Nice (IRCAN) CNRS UMR 7284/Inserm U1081; University of Nice Sophia Antipolis; Nice France
- Nice Hospital-Related Biobank BB-0033-00025; Pasteur Hospital; Nice France
| | - P. Hofman
- Laboratory of Clinical and Experimental Pathology; Pasteur Hospital; Nice Cedex France
- Institute for Research on Cancer and Aging; Nice (IRCAN) CNRS UMR 7284/Inserm U1081; University of Nice Sophia Antipolis; Nice France
- Nice Hospital-Related Biobank BB-0033-00025; Pasteur Hospital; Nice France
| |
Collapse
|
31
|
Ilie M, Hofman P. Reply to the letter to the editor ‘ALK FISH rearranged and amplified tumor with negative immunohistochemistry: a rare and challenging case concerning ALK status screening in lung cancer’ by Uguen et al. Ann Oncol 2015; 26:1802. [DOI: 10.1093/annonc/mdv225] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
32
|
Popa B, Ilie M, Plotogea O, Olteanu I, Turculet C, Constantinescu G. Ultrasound-guided drainage of walled-off pancreatic necrosis. Case report. Med Ultrason 2015; 17:259-261. [PMID: 26052581 DOI: 10.11152/mu.2013.2066.172.woff] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
ERCP (endoscopic retrograde cholangiopancreatography) represents a safe endoscopic procedure and serious complications (perforation, haemorrhage, and acute pancreatitis) are usually uncommon. We present the case of a 38-year-old patient with gallstones in the common biliary duct who developed acute pancreatitis after ERCP. One month later a huge fluid collection with necrotic tissue in the right paracolic gutter was found, the fluid being drained by percutaneous drainage under ultrasonographic guiding. The particularity of the case is the post-ERCP pancreatitis, complicated with walled-off necrosis, resolved without surgical intervention by using percutaneous drainage.
Collapse
Affiliation(s)
- Bogdan Popa
- Radiology Department, Clinical Emergency Hospital Bucharest, Romania
| | - Madalina Ilie
- Gastroenterology Department, Clinical Emergency Hospital Bucharest, Romania.
| | - Oana Plotogea
- Gastroenterology Department, Clinical Emergency Hospital Bucharest, Romania
| | - Ionut Olteanu
- Surgery Department, Clinical Emergency Hospital Bucharest, Romania
| | - Claudiu Turculet
- Surgery Department, Clinical Emergency Hospital Bucharest, Romania
| | | |
Collapse
|
33
|
Popa B, Constantinescu G, Ilie M, Badila E, Beuran M, Turculeţ C. Ileum adenocarcinoma, a missed cause of anemia. J Gastrointestin Liver Dis 2014; 23:362. [PMID: 25531989 DOI: 10.15403/jgld.2014.1121.234.iams] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]
Affiliation(s)
- Bogdan Popa
- Department of Radiology, Clinical Emergency Hospital, Bucharest, Romania
| | - Gabriel Constantinescu
- Department of Gastroenterology and Internal Medicine,Clinical Emergency Hospital, Bucharest, Romania
| | - Madalina Ilie
- Department of Gastroenterology and Internal Medicine, Clinical Emergency Hospital, Bucharest, Romania.
| | - Elisabeta Badila
- Department of Surgery, Clinical Emergency Hospital, Bucharest, Romania
| | - Mircea Beuran
- Department of Surgery, Clinical Emergency Hospital, Bucharest, Romania
| | - Claudiu Turculeţ
- Department of Surgery, Clinical Emergency Hospital, Bucharest, Romania
| |
Collapse
|
34
|
Cui H, Seubert B, Stahl E, Dietz H, Reuning U, Moreno-Leon L, Ilie M, Hofman P, Nagase H, Mari B, Krüger A. Tissue inhibitor of metalloproteinases-1 induces a pro-tumourigenic increase of miR-210 in lung adenocarcinoma cells and their exosomes. Oncogene 2014; 34:3640-50. [DOI: 10.1038/onc.2014.300] [Citation(s) in RCA: 136] [Impact Index Per Article: 13.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2013] [Revised: 07/30/2014] [Accepted: 07/31/2014] [Indexed: 12/12/2022]
|
35
|
Hofman V, Ilie M, Long E, Guibert N, Selva E, Washetine K, Mograbi B, Mouroux J, Venissac N, Reverso-Meinietti J, Milano G, Mazieres J, Marquette CH, Paterlini-Brechot P, Hofman P. Detection of Circulating Tumor Cells from Lung Cancer Patients in the Era of Targeted Therapy : Promises, Drawbacks and Pitfalls. Curr Mol Med 2014; 14:440-56. [DOI: 10.2174/1566524014666140414205455] [Citation(s) in RCA: 52] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2013] [Revised: 06/26/2013] [Accepted: 08/19/2013] [Indexed: 11/22/2022]
|
36
|
Ilie M, Long E, Hofman V, Selva E, Bonnetaud C, Boyer J, Vénissac N, Sanfiorenzo C, Ferrua B, Marquette CH, Mouroux J, Hofman P. Clinical value of circulating endothelial cells and of soluble CD146 levels in patients undergoing surgery for non-small cell lung cancer. Br J Cancer 2014; 110:1236-43. [PMID: 24473396 PMCID: PMC3950863 DOI: 10.1038/bjc.2014.11] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2013] [Revised: 12/10/2013] [Accepted: 12/12/2013] [Indexed: 12/31/2022] Open
Abstract
Background: Previous studies indicate that endothelial injury, as demonstrated by the presence of circulating endothelial cells (CECs), may predict clinical outcome in cancer patients. In addition, soluble CD146 (sCD146) may reflect activation of angiogenesis. However, no study has investigated their combined clinical value in patients undergoing resection for non-small cell lung cancer (NSCLC). Methods: Data were collected from preoperative blood samples from 74 patients who underwent resection for NSCLC. Circulating endothelial cells were defined, using the CellSearch Assay, as CD146+CD105+CD45−DAPI+. In parallel, sCD146 was quantified using an ELISA immunoassay. These experiments were also performed on a group of 20 patients with small-cell lung cancer, 60 healthy individuals and 23 patients with chronic obstructive pulmonary disease. Results: The CEC count and the plasma level of sCD146 were significantly higher in NSCLC patients than in the sub-groups of controls (P<0.001). Moreover, an increased CEC count was associated with higher levels of sCD146 (P=0.010). Both high CEC count and high sCD146 plasma level at baseline significantly correlated with shorter progression-free survival (P<0.001, respectively) and overall survival (P=0.005; P=0.009) of NSCLC patients. Conclusions: The present study provides supportive evidence to show that both a high CEC count and a high sCD146 level at baseline correlate with poor prognosis and may be useful for the prediction of clinical outcome in patients undergoing surgery for NSCLC.
Collapse
Affiliation(s)
- M Ilie
- 1] IRCAN Inserm/CNRS Team 3, CLCC Centre Antoine Lacassagne, University of Nice Sophia Antipolis, Nice, France [2] Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, Nice, France
| | - E Long
- 1] IRCAN Inserm/CNRS Team 3, CLCC Centre Antoine Lacassagne, University of Nice Sophia Antipolis, Nice, France [2] Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, Nice, France
| | - V Hofman
- 1] IRCAN Inserm/CNRS Team 3, CLCC Centre Antoine Lacassagne, University of Nice Sophia Antipolis, Nice, France [2] Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, Nice, France [3] Tumor Biobank, Pasteur Hospital, Nice, France
| | - E Selva
- Tumor Biobank, Pasteur Hospital, Nice, France
| | - C Bonnetaud
- Tumor Biobank, Pasteur Hospital, Nice, France
| | - J Boyer
- Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, Nice, France
| | - N Vénissac
- 1] IRCAN Inserm/CNRS Team 3, CLCC Centre Antoine Lacassagne, University of Nice Sophia Antipolis, Nice, France [2] Department of Thoracic Surgery, Pasteur Hospital, Nice, France
| | - C Sanfiorenzo
- 1] IRCAN Inserm/CNRS Team 3, CLCC Centre Antoine Lacassagne, University of Nice Sophia Antipolis, Nice, France [2] Department of Pneumology, Pasteur Hospital, Nice, France
| | - B Ferrua
- Inserm C3M, Archet II Hospital, Nice, France
| | - C-H Marquette
- 1] IRCAN Inserm/CNRS Team 3, CLCC Centre Antoine Lacassagne, University of Nice Sophia Antipolis, Nice, France [2] Department of Pneumology, Pasteur Hospital, Nice, France
| | - J Mouroux
- 1] IRCAN Inserm/CNRS Team 3, CLCC Centre Antoine Lacassagne, University of Nice Sophia Antipolis, Nice, France [2] Department of Thoracic Surgery, Pasteur Hospital, Nice, France
| | - P Hofman
- 1] IRCAN Inserm/CNRS Team 3, CLCC Centre Antoine Lacassagne, University of Nice Sophia Antipolis, Nice, France [2] Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, Nice, France [3] Tumor Biobank, Pasteur Hospital, Nice, France
| |
Collapse
|
37
|
Bozec A, Ilie M, Lassalle S, Hofman V, Benaim G, Long E, Santini J, Hofman P. Usefulness of ancillary methods for diagnosis, prognosis and targeted therapy in thyroid pathology. Curr Med Chem 2014; 20:639-54. [PMID: 23298138 DOI: 10.2174/092986713804999376] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2012] [Revised: 12/19/2012] [Accepted: 12/21/2012] [Indexed: 11/22/2022]
Abstract
The development of molecular analyses for thyroid pathologies is on going. These analyses provide new diagnostic tools with the aim of accurately distinguishing malignant and benign thyroid tumors. They are particularly useful as most of them can be done preoperatively on thyroid fine-needle aspiration biopsy samples. Furthermore, molecular biomarkers may play a promising role since they are able to predict the prognosis of patients with thyroid tumors. Moreover, identification of molecular markers as well as a better understanding of thyroid carcinogenesis will help develop innovative targeted therapies, particularly in patients with metastatic iodo-resistant thyroid carcinoma. To date, four types of somatic genetic alterations are known to hold potential interest for the diagnosis and/or prognosis of follicular cell-derived thyroid carcinomas: BRAF and RAS mutations, and RET/PTC and PAX8/PPARγ rearrangements. Other recent molecular biomarkers have been investigated in thyroid oncology, in particular different microRNA signatures. This review describes the different aspects of ancillary methods, including those bassed on molecular biology, that are of current interest for the diagnosis, prognosis and treatment of follicular cell-derived thyroid carcinomas.
Collapse
Affiliation(s)
- A Bozec
- Institute for Research on Cancer and Aging, Inserm U1081 & CNRS UMR 7284, Team 3, Faculty of Medicine of Nice, University of Nice Sophia Antipolis, Nice, France
| | | | | | | | | | | | | | | |
Collapse
|
38
|
Guibert N, Ilie M, Hofman V, Bordone O, Selva E, Boyer J, Lespinet V, Mollet C, Ebran N, Milano G, Vénissac N, Mouroux J, Poudenx M, Mazières J, Hugo Marquette C, Hofman P. Analyse corrélative du statut mutationnel du gène KRAS sur l’ADN libre plasmatique et les tumeurs primitives dans une série de 65 adénocarcinomes bronchiques. Approche « ciblée » versus approche à « haut débit ». Rev Mal Respir 2014. [DOI: 10.1016/j.rmr.2013.10.141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
39
|
Ilie M, Long E, Hofman V, Dadone B, Marquette C, Mouroux J, Vignaud J, Begueret H, Merlio J, Capper D, von Deimling A, Emile J, Hofman P. Diagnostic value of immunohistochemistry for the detection of the BRAF mutation in primary lung adenocarcinoma Caucasian patients. Ann Oncol 2013; 24:742-8. [DOI: 10.1093/annonc/mds534] [Citation(s) in RCA: 87] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
|
40
|
Constantinescu G, Grinţescu I, Stanciulescu L, Ilie M, Beuran M, Chiotoroiu A. A rare cause of acute massive lower gastrointestinal bleeding. Chirurgia (Bucur) 2013; 108:102-105. [PMID: 23464779] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/01/2013] [Indexed: 06/01/2023]
Abstract
Even if lower gastrointestinal bleeding (LGIB) can present as trivial haematochezia, massive hemorrhage with shock may occur. Acute massive LGIB is defined as bleeding of recent duration that originates beyond the ligament of Treitz and encompasses: passage of a large volume of red or maroon blood through the rectum, haemodynamic instability and shock, initial decrease in haematocrit level of 6 g/dL or less, transfusion of at least 2 U of packed red blood cells, bleeding that continues for 3 days or significant rebleeding in 1 week. This report presents the case of a 58-year-old man with massive LGI bleeding. Colonoscopy was performed in emergency with a poor colonic preparation, but the examiner fortunately and with difficulty managed to identify the source of the haemorrhage- a Dieulafoy's lesion of the right colon. The bleeding was successfully stopped permanently by injecting sclerosing agents into the spurting vessel. We have preferred colonoscopy as our first choice of investigation due to the facile availability and the opportunity of endoscopic haemostasis in case of finding the source of bleeding. Angiography was planned in case of failure of the first method. The definition, clinical presentation, and treatment of Dieulafoy's lesion are further discussed.
Collapse
|
41
|
Giacchero D, Ilie M, Long E, Selva E, Duteil L, Bahadoran P, Hofman P, Lacour JP. Valeur pronostique de la détection de cellules tumorales circulantes au cours du mélanome métastatique. Ann Dermatol Venereol 2012. [DOI: 10.1016/j.annder.2012.10.138] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
42
|
Hofman V, Ilie M, Long E, Butori C, Lespinet V, Bordone O, Bonnetaud C, Marquette CH, Vénissac N, Mouroux J, Hofman P. Analyse du statut mutationnel du gène KRAS à partir de 442 adénocarcinomes bronchopulmonaires d’une population française caucasienne : corrélation avec le statut tabagique, les sous-types histologiques, le stade pTNM et l’évolution clinique. Ann Pathol 2012. [DOI: 10.1016/j.annpat.2012.09.142] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
43
|
Ilie M, Long E, Butori C, Hofman V, Coelle C, Mauro V, Zahaf K, Marquette CH, Mouroux J, Paterlini-Bréchot P, Hofman P. ALK-gene rearrangement: a comparative analysis on circulating tumour cells and tumour tissue from patients with lung adenocarcinoma. Ann Oncol 2012; 23:2907-2913. [PMID: 22735679 DOI: 10.1093/annonc/mds137] [Citation(s) in RCA: 136] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023] Open
Abstract
BACKGROUND A subgroup of anaplastic lymphoma kinase (ALK)-rearranged lung tumours can respond to ALK inhibitors. Until now, the ALK status in circulating tumour cells (CTCs) isolated from patients with lung cancer has not been characterised. We assessed the ALK status in CTCs detected in patients with lung cancer and correlated the results to the ALK status defined in the corresponding tumour tissue. PATIENTS AND METHODS A total of 87 patients with lung adenocarcinoma showing CTCs isolated using the isolation by size of epithelial tumour cell method were screened for their ALK status both in tumour samples and in CTCs. ALK break-apart fluorescence in situ hybridisation (FISH) and immunoreactivity analyses using an anti-ALK antibody (5A4 clone) were carried out on CTCs and compared with the results obtained in the corresponding tissue specimens. RESULTS A total of five patients showed ALK-gene rearrangement and strong ALK protein expression in CTCs and in the corresponding tumour samples. Both ALK-FISH and ALK immunoreactivity analyses show negative results in CTCs and corresponding tumour samples for 82 patients. Conclusions We demonstrated that the ALK status can be determined in CTCs isolated from patients with lung cancer by immunocytochemistry and FISH analyses. These results favour non-invasive, ALK-gene status pre-screening on a routine basis on CTCs isolated from patients with lung cancer and open new avenues for real-time monitoring for adapted targeted therapy.
Collapse
Affiliation(s)
- M Ilie
- Institute for Research on Cancer and Ageing (IRCAN), INSERM U1081, CNRS UMR 7284, Team 3, Nice; Team 3, Faculty of Medicine, University of Nice Sophia Antipolis, Nice; Human Biobank Unit; Laboratory of Clinical and Experimental Pathology, University Hospital Centre of Nice, Pasteur Hospital, Nice; Cancéropôle PACA, Marseille
| | - E Long
- Institute for Research on Cancer and Ageing (IRCAN), INSERM U1081, CNRS UMR 7284, Team 3, Nice; Team 3, Faculty of Medicine, University of Nice Sophia Antipolis, Nice; Laboratory of Clinical and Experimental Pathology, University Hospital Centre of Nice, Pasteur Hospital, Nice
| | - C Butori
- Laboratory of Clinical and Experimental Pathology, University Hospital Centre of Nice, Pasteur Hospital, Nice
| | - V Hofman
- Institute for Research on Cancer and Ageing (IRCAN), INSERM U1081, CNRS UMR 7284, Team 3, Nice; Team 3, Faculty of Medicine, University of Nice Sophia Antipolis, Nice; Human Biobank Unit; Laboratory of Clinical and Experimental Pathology, University Hospital Centre of Nice, Pasteur Hospital, Nice; Cancéropôle PACA, Marseille
| | | | | | - K Zahaf
- Laboratory of Clinical and Experimental Pathology, University Hospital Centre of Nice, Pasteur Hospital, Nice
| | - C H Marquette
- Institute for Research on Cancer and Ageing (IRCAN), INSERM U1081, CNRS UMR 7284, Team 3, Nice; Team 3, Faculty of Medicine, University of Nice Sophia Antipolis, Nice; Department of Pneumology
| | - J Mouroux
- Institute for Research on Cancer and Ageing (IRCAN), INSERM U1081, CNRS UMR 7284, Team 3, Nice; Team 3, Faculty of Medicine, University of Nice Sophia Antipolis, Nice; Department of Thoracic Surgery, University Hospital Centre of Nice, Pasteur Hospital, Nice
| | | | - P Hofman
- Institute for Research on Cancer and Ageing (IRCAN), INSERM U1081, CNRS UMR 7284, Team 3, Nice; Team 3, Faculty of Medicine, University of Nice Sophia Antipolis, Nice; Human Biobank Unit; Laboratory of Clinical and Experimental Pathology, University Hospital Centre of Nice, Pasteur Hospital, Nice; Cancéropôle PACA, Marseille.
| |
Collapse
|
44
|
Lassalle S, Long E, Hofman V, Ilie M, DeMicco C, Patey M, Tissier F, Belléannée G, Trouette H, Catargi B, Peyrottes I, Sadoul JL, Bordone O, Bonnetaud C, Guevara N, Santini J, Lemaire G, Blank O, Vielh P, Mari B, Hofman P. Mise en évidence d’une signature microARN pouvant différentier les carcinomes médullaires de la thyroïde héréditaires des formes sporadiques. Ann Pathol 2012. [DOI: 10.1016/j.annpat.2012.09.116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
45
|
Ilie M, Long E, Butori C, Hofman V, Coelle C, Mauro V, Zahaf K, Marquette CH, Mouroux J, Paterlini-Bréchot P, Hofman P. Le réarrangement du gène EML4-ALK : analyse comparative sur les cellules tumorales circulantes et le tissu tumoral à partir de 87 cas d’adénocarcinomes pulmonaires. Ann Pathol 2012. [DOI: 10.1016/j.annpat.2012.09.139] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
46
|
Bozec A, Ilie M, Long E, Dassonville O, Poissonnet G, Santini J, Chamorey E, Peyrade F, Benezery K, Sudaka A, Selva E, Hofman P. Détection des cellules tumorales circulantes par la méthode CellSearch dans les carcinomes épidermoïdes de la tête et du cou de stade IIIb et IV. Ann Pathol 2012. [DOI: 10.1016/j.annpat.2012.09.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
47
|
Hofman P, Juhel T, Ilie M, Bordone O, Boyer O, Hebuterne X, Adriouch S, Vouret-Craviari V. L’activation du récepteur purinergique P2X7 protège les souris d’une carcinogenèse colique induite par l’inflammation. Ann Pathol 2012. [DOI: 10.1016/j.annpat.2012.09.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
48
|
Ilie M, Lassalle S, Brest P, Bonnetaud C, Bozec A, Guevara N, Haudebourg J, Peyrottes I, Santini J, Hofman P. Corrélation de l’expression protéique de TIMP-1, CAIX, CAXII et HIF-1α avec le statut BRAFV600E et l’évolution clinique des carcinomes papillaires de la thyroïde. Ann Pathol 2012. [DOI: 10.1016/j.annpat.2012.09.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
49
|
Belaid A, Cerezo M, Chargui A, Corcelle-Termeau E, Pedeutour F, Giuliano S, Ilie M, Rubera I, Tauc M, Barale S, Bertolotto C, Brest P, Vouret-Craviari V, Klionsky D, Carle G, Hofman P, Mograbi B. Rôle de l’autophagie dans la progression tumorale des carcinomes pulmonaires non à petites cellules. Ann Pathol 2012. [DOI: 10.1016/j.annpat.2012.09.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
50
|
Ilie M, Hofman P. Pitfalls in Lung Cancer Molecular Pathology: How to Limit them in Routine Practice? Curr Med Chem 2012; 19:2638-51. [DOI: 10.2174/092986712800493002] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2011] [Revised: 03/12/2012] [Accepted: 03/14/2012] [Indexed: 11/22/2022]
|